Here, our aims were to determine if combining a behavioral assessment (informed by MBI criteria) together with a cognitive assessment (informed by MCI criteria) would identify a subgroup with: 1) greater baseline AD pathology (β-amyloid42, p-tau, t-tau); 2) greater change in AD biomarker levels over 4 years; and 3) greater 4-year incidence rate of dementia, specifically AD. The gene discussed is MAPT; the disease is Alzheimer disease.